Journal article icon

Journal article

Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review.

Abstract:

BACKGROUND: Infliximab (IFX) is a chimeric (mouse/human) anti-TNF-alpha monoclonal antibody approved for the treatment of refractory luminal and fistulizing Crohn's disease (CD). It is a source of potential immunogenicity for humans, with the occurrence of anti-infliximab antibodies (ATIs), which are thought to interfere with the pharmacodynamics and/or pharmacokinetics of the compound. It remains unclear whether ATIs have any clinical importance for drug efficacy or safety. We review studie...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1002/ibd.20899

Authors


Cassinotti, A More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Medicine, Experimental Medicine Division,
Journal:
Inflammatory bowel diseases
Volume:
15
Issue:
8
Pages:
1264-1275
Publication date:
2009-08-05
DOI:
EISSN:
1536-4844
ISSN:
1078-0998
URN:
uuid:3579dda0-2822-4e2d-8bcc-7c930b37d4c9
Source identifiers:
112090
Local pid:
pubs:112090

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP